, median progression-free survival (PFS) was modestly but not statistically significantly prolonged, with 36.0 months with bortezomib and dexamethasone versus 29.7 months with VAD. 76 Use of DCEP as consolidation therapy after primary therapy did not have
Search Results
Multiple Myeloma, Version 2.2016
Kenneth C. Anderson, Melissa Alsina, Djordje Atanackovic, J. Sybil Biermann, Jason C. Chandler, Caitlin Costello, Benjamin Djulbegovic, Henry C. Fung, Cristina Gasparetto, Kelly Godby, Craig Hofmeister, Leona Holmberg, Sarah Holstein, Carol Ann Huff, Adetola Kassim, Amrita Y. Krishnan, Shaji K. Kumar, Michaela Liedtke, Matthew Lunning, Noopur Raje, Seema Singhal, Clayton Smith, George Somlo, Keith Stockerl-Goldstein, Steven P. Treon, Donna Weber, Joachim Yahalom, Dorothy A. Shead, and Rashmi Kumar
Monitoring Minimal Residual Disease in Acute Myeloid Leukemia: Ready for Prime Time?
Farhad Ravandi and Jeffrey L. Jorgensen
induction and consolidation therapy. On multivariate analysis, postconsolidation MRD status independently affected relapse rate, overall survival, and relapse-free survival ( P < .001, for all comparisons). 21 Vinditti et al., 22 , 23 recently confirmed
Experimental Therapies and Clinical Trials in Bone Sarcoma
Rashmi Chugh
-dose therapy for patients with newly diagnosed localized or metastatic EWS (NCT00020566). After initial induction chemotherapy and local therapy, patients undergo risk-stratified consolidation therapy ( Figure 1 ). Patients who experience poor response (R2) are
Optimize Local Therapy for Oligometastatic and Oligoprogressive Non–Small Cell Lung Cancer to Enhance Survival
Joe Y. Chang and Vivek Verma
consolidative therapy vs. maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer: long-term results of a multi-institutional, phase II, randomized study . J Clin Oncol 2019 ; 37 : 1558 – 1565 . 10.1200/JCO.19
Identifying Older Patients With Acute Myeloid Leukemia Who May Be Candidates for Reduced-Intensity Hematopoietic Cell Transplantation
Boglarka Gyurkocza and Frederick R. Appelbaum
patient with AML should involve, among other considerations, the assessment of outcomes with standard consolidation therapy. Although long-term remission rates with chemotherapy may approach 40% in some groups of adult patients, the standard chemotherapy
Evolving Paradigms in the Treatment of Newly Diagnosed Multiple Myeloma
Alessandra Larocca and Antonio Palumbo
Cavo M Tacchetti P Patriarca F . Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed
Management of Relapsed and Relapsed/Refractory Multiple Myeloma
Jacob P. Laubach, Constantine S. Mitsiades, Anuj Mahindra, Marlise R. Luskin, Jacalyn Rosenblatt, Irene M. Ghobrial, Robert L. Schlossman, David Avigan, Noopur Raje, Nikhil C. Munshi, Kenneth C. Anderson, and Paul G. Richardson
, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study . Lancet 2010 ; 376 : 2075 – 2085 . 12 Rajkumar SV Jacobus S Callander NS . Lenalidomide plus
Optimization of Postremission Therapy in Follicular Lymphoma: Efficacy of Rituximab Maintenance
Rupali Roy and Leo I. Gordon
grade 3 or 4 infection-related adverse events was significantly higher in patients receiving rituximab maintenance/consolidation therapy than in those undergoing observation (relative risk, 2.9; 95% CI, 1.21–3.27). 43 In long-term follow-up of the EORTC
The Role of CAR T-Cell Therapy in Relapsed/Refractory Adult B-ALL
Tamer Othman, Aaron C. Logan, Lori Muffly, Jessica Leonard, Jae Park, Bijal Shah, and Ibrahim Aldoss
, Consolidation therapy with blinatumomab improves overall survival in newly diagnosed adult patients with B-lineage acute lymphoblastic leukemia in measurable residual disease negative remission: results from the ECOG-ACRIN E1910 randomized phase III National
Progressive Multifocal Leukoencephalopathy After Allogeneic Bone Marrow Transplantation for Acute Myeloid Leukemia
Hans C. Lee, Victor Mulanovich, and Yago Nieto
. a complete remission, and then received 2 additional cycles as consolidation therapy. The patient then experienced disease relapse and achieved a second remission after treatment with high-dose cytarabine and vosaroxin followed by decitabine. He then